Trials / Conditions / Schizophrenic Disorders

Schizophrenic Disorders

21 registered clinical trials studyying Schizophrenic Disorders.

Status	Trial	Sponsor	Phase
Terminated	Interest of EMDR Schizophrenic Disorders NCT05164289	Hôpital NOVO	—
Unknown	Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia NCT04608032	Centre hospitalier de Ville-Evrard, France	N/A
Completed	Have a Good Grasp of the Worldthe World NCT02655172	Centre Hospitalier Universitaire de Saint Etienne	N/A
Withdrawn	Sodium Butyrate For Improving Cognitive Function In Schizophrenia NCT02654405	Nathan Kline Institute for Psychiatric Research	Phase 2 / Phase 3
Completed	Upside Down, Give me the Handle NCT02544516	Centre Hospitalier Universitaire de Saint Etienne	N/A
Completed	Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) NCT01729650	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	N/A
Completed	A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Sch NCT01606436	Denovo Biopharma LLC	Phase 1
Completed	D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia NCT00960219	China Medical University Hospital	Phase 2
Completed	Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia NCT01279213	Universidad Nacional de Rosario	Phase 4
Terminated	Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose NCT00660595	AstraZeneca	Phase 3
Completed	Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone NCT00600756	AstraZeneca	Phase 3
Completed	Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations NCT02525315	University Hospital, Caen	Phase 2
Completed	Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. NCT00488319	Janssen Research & Development, LLC	Phase 3
Completed	The Psychiatric Rehabilitation Approach to Weight Loss NCT00572247	University of Kansas	N/A
Withdrawn	Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia NCT00276263	Herzog Hospital	Phase 2
Completed	Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia NCT00491569	China Medical University Hospital	Phase 2
Completed	Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia NCT00328276	China Medical University Hospital	Phase 2
Completed	Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder NCT00088465	Eli Lilly and Company	Phase 3
Completed	Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophre NCT00088491	Eli Lilly and Company	Phase 3
Completed	Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia NCT00485823	Eli Lilly and Company	Phase 4
Unknown	Psychological Intervention for Relapse Prevention in First Episode Schizophrenia NCT00161408	University Hospital Tuebingen	N/A